Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ingevity (NGVT) EBT (2016 - 2025)

Ingevity (NGVT) has disclosed EBT for 11 consecutive years, with -$105.4 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 537.34% to -$105.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$142.1 million, a 1.14% decrease, with the full-year FY2025 number at -$142.1 million, down 1.14% from a year prior.
  • EBT was -$105.4 million for Q4 2025 at Ingevity, down from $79.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $241.9 million in Q3 2024 to a low of -$334.6 million in Q2 2024.
  • A 5-year average of $14.0 million and a median of $34.2 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 1164.44% in 2022, then plummeted 801.47% in 2024.
  • Ingevity's EBT stood at $36.3 million in 2021, then plummeted by 45.73% to $19.7 million in 2022, then tumbled by 170.56% to -$13.9 million in 2023, then skyrocketed by 273.38% to $24.1 million in 2024, then tumbled by 537.34% to -$105.4 million in 2025.
  • Per Business Quant, the three most recent readings for NGVT's EBT are -$105.4 million (Q4 2025), $79.2 million (Q3 2025), and -$142.7 million (Q2 2025).